Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
21-40 of 936 trials

Rod Cone Dystrophy: SPVN06 Gene Therapy

We are evaluating the safety and tolerability of a new gene therapy for patients with rod cone dystrophy. This study aims to understand how well the treatment is tolerated in this specific group.

Hereditary Retinal Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)Ophthalmology

Pembrolizumab for Children with Advanced Melanoma and Solid Tumors

We are studying the safety and effectiveness of pembrolizumab in children with advanced melanoma or certain relapsed solid tumors and lymphoma. This trial aims to understand how well this treatment works and its potential side effects.

Advanced Melanoma and Related CancersSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Myeloid Diseases: DFV890 Treatment Study

We are investigating the safety and effectiveness of DFV890 in adults with myeloid diseases. This study aims to understand how well this treatment works and how it is tolerated.

Myeloid Dysplasia>2 yearsSafety phase (I)HematologyOncology

Advanced Solid Tumors: Sacituzumab Govitecan Study

We are exploring a new medication for patients with advanced or metastatic solid tumors who also have moderate liver impairment. The goal is to find a safe starting dose for this treatment.

Solid Tumors≤3 monthsSafety phase (I)HepatologyOncology

Breast Cancer: Ribociclib with Hormone Therapy and Radiotherapy

We are studying the safety and effectiveness of Ribociclib combined with hormone therapy and radiotherapy for elderly patients with hormone-positive, HER2-negative breast cancer. This trial is for those newly diagnosed who are not ready for surgery.

Breast Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesEndocrinologyOncology

Advanced Solid Tumors: MK-1084 Treatment

We are testing a new drug, MK-1084, for patients with advanced solid tumors that have a KRAS mutation. This study aims to understand its safety and how it may help in treating these tumors.

Solid Tumor Cancer>2 yearsSafety phase (I)Oncology

Solid Tumors: AZD9592 Treatment Study

We are testing a new drug called AZD9592 for patients with solid tumors. The goal is to learn more about its safety and how it may help in treating cancer.

Metastatic Colorectal CancerRecurrent or Metastatic Head and Neck Squamous Cell CarcinomaLocally Advanced or Metastatic Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Oncology

Advanced Solid Tumors: ASP3082 Study

We are investigating a new treatment called ASP3082 for adults with advanced solid tumors. The goal is to learn more about its effects and safety in this patient group.

Solid Tumor>2 yearsSafety phase (I)Oncology

Long-Term Safety of Miltenyi CAR T Cell Therapy

We are studying the long-term effects of Miltenyi CAR T cell therapy on patients, especially children. This includes monitoring safety, disease progression, and overall survival.

Unresectable Stage III or IV MelanomaRelapsed or Refractory B Cell Non-Hodgkin's LymphomaRelapsed or Refractory CD20 Positive B-Cell Non-Hodgkin’s Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyHematologyOncology

Advanced Solid Tumors: Denikitug Treatment Study

We are testing a new antibody treatment for adults with advanced solid tumors to see if it is safe and effective. This study looks at the treatment alone and in combination with another therapy.

Various Types of Cancer>2 yearsSafety phase (I)Oncology

Neuroblastoma: Comparing PET-CT and SPECT-CT Scans

We are studying whether a new PET-CT scan can better detect lesions in patients with neuroblastoma compared to a standard SPECT-CT scan. This may help improve diagnosis and treatment options for patients.

Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Novel Amino Acid PET Tracer: [18F]FELP

We are testing a new imaging agent to see how well it works in detecting certain diseases. This study aims to improve the accuracy of PET scans for better diagnosis.

Glioblastoma>2 yearsSafety phase (I)Oncology

GD2 Positive Solid Cancers: GD2IL18CART Treatment

We are testing a new therapy called GD2IL18CART for patients with relapsed or hard-to-treat GD2 positive solid cancers. The study aims to assess safety, find the right dose, and evaluate how well the treatment works.

NeuroblastomaAdvanced Breast CancerEwing Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Brain Tumor Treatment: BI 764532 Dosing Study

We are testing how well different doses of BI 764532 are tolerated by people with brain tumors that are positive for DLL3. This study aims to ensure the safety of the medication for future use.

Glioma1-2 yearsSafety phase (I)NeurologyOncology

Blood Cancer Treatment: Allo-RevCAR01-T-CD123

We are testing a new therapy for patients with certain blood cancers that have CD123 markers. This study aims to evaluate the safety and dosage of this innovative treatment.

Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Myeloma: [68Ga]Ga-PentixaFor PET Imaging Study

We are studying a new imaging method to see how accurately it detects myeloma at the beginning of treatment. This may help improve risk assessment and disease management for patients.

Multiple Myeloma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Small-Cell Lung Cancer: BI 764532 Study

We are testing how well the drug BI 764532 is taken up by tumors in patients with small-cell lung cancer or neuroendocrine cancer. This study aims to understand its potential effectiveness in treating these cancers.

Advanced CancerLarge Cell Neuroendocrine Lung Carcinoma (LCNEC)Neuroendocrine Carcinoma (NEC)>2 yearsSafety phase (I)Oncology

Glioblastoma: L19TNF and Lomustine Study

We are evaluating a new treatment combining L19TNF with lomustine for patients with glioblastoma at their first progression. This study aims to understand how safe and effective this combination is.

Glioblastoma>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Pancreatic Cancer: KISIMA-02 Vaccine Therapy

We are testing a new vaccine-based immunotherapy for patients with pancreatic cancer. This study aims to see if it can enhance the effectiveness of current treatments.

Pancreatic Cancer>2 yearsSafety phase (I)Oncology

Leukemia and Lymphoma: Dasatinib and Venetoclax Study for Children

We are testing two new drugs for children with relapsed or refractory leukemia or lymphoma that have specific genetic mutations. The goal is to assess safety and see if these drugs can effectively treat their condition.

Lymphoblastic Lymphoma and Acute Lymphoblastic Leukemia1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementHematologyOncology